Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of bimatoprost solution on scalp hair
growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment
of glaucoma (Lumigan™) and for thickening of thin eyelashes (Latisse™). Bimatoprost 0.03% is
not approved for the treatment of scalp hair loss and its use in this study is considered
investigational which means it is still being tested in research studies.
Thirty-three subjects were consented and screened, 9 entered and 9 completed the study.